TOKYO and HENNIGSDORF, Germany, Oct. 3, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., “Pantherna”) right now introduced that the businesses have entered into a brand new expertise analysis settlement for analysis to generate mRNA-based regenerative drugs packages utilizing direct reprogramming (transdifferentiation)*.

This settlement expands the scope of the expertise analysis settlement for analysis, which Astellas and Pantherna entered into in 2021, to incorporate new goal organ.

Pantherna owns a proprietary platform of state-of-the-art, distinctive mRNA molecules (PTXmRNAs) for enhancing the effectivity of mRNA actions within the physique. Beneath the brand new settlement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will probably be mixed to advertise analysis on the technology of regenerative drugs packages for brand new goal organ utilizing a direct reprogramming strategy. Astellas will probably be answerable for offering drug discovery concepts, getting ready candidate compounds for expertise analysis, and performing analysis aimed toward growing this therapeutic modality, whereas Pantherna will probably be answerable for offering technical data and improvement help.

“We’re enthusiastic about this growth of our collaboration with Astellas,” mentioned Pantherna’s Chief Govt Officer, Klaus Giese, Ph.D. “We really feel honored that Astellas, as a number one pharmaceutical firm, has underscored their curiosity in leveraging the distinctive features of our proprietary therapeutic mRNA expertise.”

“By this settlement, which expands the scope of our collaboration with Pantherna, we’ll create modern regenerative drugs packages for brand new goal organ, and we anticipate that we can thereby increase the therapy choices for illnesses with excessive unmet medical wants.” mentioned Taiji Sawamoto, Ph.D., Govt Vice President, Utilized Analysis & Operations, at Astellas. “The collaboration with Pantherna is an initiative which synergistically integrates Astellas’ experience with mRNA as a therapeutic modality and its capabilities cultivated within the analysis area of direct reprogramming, and can promote the event of next-generation therapies utilizing a brand new modality/expertise based mostly on the Focus Space strategy technique.”

* Direct reprogramming: Direct conversion of the destiny of cells with out passing by means of the pluripotent state.

About Astellas
Astellas Pharma Inc. is a pharmaceutical firm conducting enterprise in additional than 70 international locations world wide. We’re selling the Focus Space Method that’s designed to determine alternatives for the continual creation of latest medication to deal with illnesses with excessive unmet medical wants by specializing in Biology and Modality. Moreover, we’re additionally wanting past our foundational Rx focus to create Rx+® healthcare options that mix our experience and data with cutting-edge expertise in numerous fields of exterior companions. By these efforts, Astellas stands on the forefront of healthcare change to show modern science into worth for sufferers. For extra data, please go to our web site at

About Pantherna
Pantherna Therapeutics is a privately held biopharmaceutical firm growing first-in-class therapeutics for vascular illnesses. Pantherna’s modern expertise platform is predicated on superior lipid nanoparticles for the target-specific, selective supply and expression of therapeutic mRNA medication in organs and tissues such because the endothelium. Pantherna Therapeutics was lately awarded with a 2022 Pharma Pattern Honor for its lead candidate PAN004 within the class “Most Revolutionary Product: Leap Improvements-Nucleic Acid-Based mostly Drug Improvement”

( Pantherna is predicated in Hennigsdorf, Brandenburg (Innovationsforum) near Berlin, Germany. For extra data, please go to our web site at

Cautionary Notes (Astellas)
On this press launch, statements made with respect to present plans, estimates, methods and beliefs and different statements that aren’t historic information are forward-looking statements concerning the future efficiency of Astellas. These statements are based mostly on administration’s present assumptions and beliefs in mild of the knowledge presently accessible to it and contain recognized and unknown dangers and uncertainties. Quite a lot of components might trigger precise outcomes to vary materially from these mentioned within the forward-looking statements. Such components embody, however usually are not restricted to: (i) modifications usually financial circumstances and in legal guidelines and laws, regarding pharmaceutical markets, (ii) foreign money change charge fluctuations, (iii) delays in new product launches, (iv) the lack of Astellas to market current and new merchandise successfully, (v) the lack of Astellas to proceed to successfully analysis and develop merchandise accepted by prospects in extremely aggressive markets, and (vi) infringements of Astellas’ mental property rights by third events.

Details about pharmaceutical merchandise (together with merchandise presently in improvement) which is included on this press launch will not be supposed to represent an commercial or medical recommendation.

SOURCE Astellas Pharma Inc.

Source link


Please enter your comment!
Please enter your name here